Nasal spray for multiple system atrophy (MSA) study
Part of Brain & nervous system clinical trials.
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of multiple system atrophy (MSA).
- You are between 30 and 85 years old.
- Your Parkinson's medications have been stable for at least 4 weeks before joining.
- You do not have other serious health problems like active infections, severe heart disease, or certain autoimmune conditions.
- You are willing and able to use a nasal spray and undergo MRI scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This trial tests a new antibody therapy that may target and remove abnormal proteins in the brain linked to Multiple System Atrophy (MSA). It aims to see if the treatment is safe and whether it can help slow the progression of the disease.
This study tests whether a drug called butylphthalide can safely help people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions like blood pressure. Participating may help slow the progression of symptoms and improve quality of life.
This trial tests a new stem cell treatment for people with multiple system atrophy (MSA), a rare brain disorder that affects movement and automatic body functions. The treatment uses stem cells from healthy donors, which may help slow down the disease.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
This study looks at how the body handles blood sugar (insulin resistance) in people with multiple system atrophy (MSA). Results may help doctors understand the disease better and explore new ways to monitor or treat it.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.